Evenity (Romosozumab) and Exercise: What to Do, What to Avoid, and How to Move Safely on This Medication

Why Exercise Matters While You Are on Romosozumab

Romosozumab works by inhibiting sclerostin, a protein that normally brakes bone formation. Removing that brake drives a rapid, dual-action effect: bone formation goes up and bone resorption goes down simultaneously, at least during the first few months of treatment. This mechanism makes the 12-month treatment window a narrow but powerful opportunity to build structural bone. Exercise amplifies that window.

Bone cells called osteoblasts respond to mechanical load, a principle called Wolff's Law. When a muscle contracts against resistance or when ground-reaction forces travel through the skeleton during walking or jogging, osteoblasts receive biochemical signals to deposit new bone matrix. Romosozumab is already stimulating those same osteoblasts pharmacologically. Adding mechanical load therefore works on the same cellular machinery from a second direction.

The Evidence Linking Exercise to Bone Density Gains

A meta-analysis published in the Journal of Bone and Mineral Research found that combined resistance and impact exercise increased lumbar spine BMD by a mean of 1.5% and femoral neck BMD by 0.9% in postmenopausal women over 6 to 12 months (Zhao et al., 2017). Those numbers are modest on their own, but stacked on top of the gains romosozumab produces, they become clinically meaningful.

The FRAME trial (N=7,180) demonstrated that 12 months of romosozumab 210 mg monthly increased lumbar spine BMD by 13.3% and total hip BMD by 6.9% versus placebo, while cutting new vertebral fracture risk by 73% (Cosman et al., NEJM 2016). Exercise-related gains sit on top of that pharmacological foundation.

What the Endocrine Society Says

The Endocrine Society's 2019 clinical practice guideline on osteoporosis states: "We recommend weight-bearing and muscle-strengthening exercise to reduce the risk of falls and fractures." (Eastell et al., J Clin Endocrinol Metab 2019). That recommendation applies specifically to patients on anabolic therapy, the drug class that includes romosozumab.

Cardiovascular Safety: The Most Important Consideration Before You Start

Romosozumab carries an FDA boxed warning for major adverse cardiovascular events (MACE), including heart attack and stroke. The ARCH trial (N=4,093) found that patients on romosozumab followed by alendronate had a slightly higher rate of MACE in the first 12 months compared with patients on alendronate alone (2.5% vs. 1.9%, P=0.07) (Saag et al., NEJM 2017). The FDA formally added the MACE boxed warning to the label in 2019 based on this signal.

This does not mean exercise is contraindicated. Moderate exercise is cardioprotective. The point is that patients who have had a heart attack or stroke within the past 12 months should not be prescribed romosozumab at all per FDA labeling, and patients with significant cardiovascular risk factors should get clearance from their cardiologist or primary care physician before beginning a vigorous new exercise program.

Who Needs a Cardiology Consult First

Patients with any of the following should speak with their prescribing clinician before starting a new or significantly more intense exercise regimen while on romosozumab:

• History of myocardial infarction or ischemic stroke in the past 12 months
• Unstable angina or recent coronary revascularization
• New or worsening chest pain, dyspnea, or palpitations
• Uncontrolled hypertension (systolic above 160 mmHg at rest)

For patients without those risk factors, moderate-intensity aerobic and resistance exercise is appropriate to start or continue without additional cardiac testing, consistent with the American Heart Association's pre-participation screening guidance (AHA, Circulation 2007).

Exercise Intensity Categories That Apply Here

The AHA defines moderate-intensity exercise as activity that raises heart rate to 50 to 70 percent of age-predicted maximum. At that level, cardiovascular benefit outweighs risk for most patients with osteoporosis. Vigorous exercise, defined as above 70 percent of maximum heart rate, requires the clearance considerations described above.

The Best Exercise Types for Patients on Romosozumab

Not all exercise is equal for bone health. The type, intensity, and loading pattern matter significantly. The National Osteoporosis Foundation and the American College of Sports Medicine both publish exercise recommendations specifically for people with osteoporosis.

Weight-Bearing Aerobic Exercise

Walking, jogging, dancing, stair climbing, and low-impact aerobics all qualify as weight-bearing. Ground-reaction forces during these activities stimulate bone remodeling in the hip and spine, exactly the sites where osteoporotic fractures are most dangerous. A prospective study in the Journal of Bone and Mineral Research found that postmenopausal women who walked at least 4 hours per week had a 41% lower hip fracture risk compared with those who walked less than 1 hour per week (Feskanich et al., 2002).

Aim for 30 minutes of moderate-intensity weight-bearing activity on most days of the week, consistent with guidelines from the Centers for Disease Control and Prevention for adults aged 65 and older (CDC Physical Activity Guidelines).

Resistance Training

Muscle contractions during resistance training generate compressive and tensile forces directly in bone. The spine and hip respond to these forces with net bone formation, especially when loads are progressive. A Cochrane systematic review of 43 trials found that resistance training significantly improved lumbar spine BMD in postmenopausal women (standardized mean difference 0.57, 95% CI 0.04 to 1.10) (Howe et al., Cochrane 2011).

For patients on romosozumab, a twice-weekly program targeting the major muscle groups, particularly the hip extensors, quadriceps, back extensors, and shoulders, is a reasonable starting point. Start with machines or body weight if free-weight balance is uncertain.

Balance and Proprioception Training

Falls cause fractures. A Cochrane review of 108 trials (N=23,407 participants) found that exercise programs focusing on balance and functional training reduced fall rates by 23% in community-dwelling older adults (Sherrington et al., Cochrane 2019). Tai chi, single-leg stands, tandem walking, and stepping exercises all develop the proprioceptive control that prevents stumbles from becoming fractures.

During the 12 months on romosozumab, your bone is getting stronger. But until DXA confirms those gains, any fall remains dangerous. Balance training is therefore one of the highest-yield investments you can make while taking this drug.

Exercises to Approach With Caution or Avoid

Some exercise patterns can increase fracture risk in people with osteoporosis, regardless of whether they are on romosozumab. The National Osteoporosis Foundation cautions against the following (NOF Exercise Guide, referenced via NIH OsteoporInfo):

• High-impact activities with repeated jarring: running on hard surfaces at high speeds, jumping, box jumps
• Forward spinal flexion under load: sit-ups, certain yoga poses like deep forward folds, rowing with a rounded back
• Twisting the spine against resistance: rotational core exercises that load the spine at end range
• Contact and collision sports: basketball, soccer, martial arts with full contact

This does not mean these activities are universally forbidden. Patients with milder baseline bone density loss may tolerate some of these activities. The decision should be made individually with your prescribing clinician and a physical therapist familiar with osteoporosis management.

Swimming and Cycling: Useful but Incomplete

Swimming and cycling are excellent for cardiovascular fitness and muscle conditioning. They carry very low fall risk. The limitation is that neither provides meaningful axial loading on the spine or hip, so they do not drive the bone formation response that weight-bearing and resistance exercise do. Use them as supplementary activities, not as the primary bone-health intervention.

Exercising on Injection Day

Romosozumab is given as two subcutaneous injections of 105 mg each (total 210 mg) in the abdomen, thigh, or upper arm, once per month. The most common injection-site reactions are erythema, pain, and bruising. These occur in roughly 4 to 5% of patients in clinical trials (FDA Evenity Prescribing Information).

Light to moderate exercise on injection day is generally well-tolerated. Avoid direct pressure or repetitive friction over the injection site, so skip exercises that involve lying on or strapping equipment over the injected area for the first 24 hours. Beyond that, no pharmacokinetic reason exists to restrict exercise on injection day. Romosozumab has a half-life of approximately 6.9 days and is not affected by physical activity.

Physical Therapy: When to Ask for a Referral

A physical therapist with osteoporosis training can perform a formal fall-risk assessment, design a progressive loading program calibrated to your current strength and balance, and teach spine-protective movement mechanics for daily activities. The American Physical Therapy Association supports the use of structured PT programs in patients with osteoporosis receiving pharmacotherapy.

Patients who have had a recent fracture, who score poorly on the Timed Up and Go test (above 12 seconds signals elevated fall risk), or who are deconditioned after a period of inactivity should prioritize a PT referral before beginning unsupervised exercise. Your prescribing clinician can generate this referral at any point during your 12-month romosozumab course.

A Practical 3-Phase Exercise Framework for the 12-Month Romosozumab Course

Phase 1 (Months 1 to 3): Foundation. Focus on balance training, posture correction, and light resistance with bodyweight or resistance bands. Primary goal is fall-risk reduction and movement-pattern safety. Frequency: 3 to 4 days per week, sessions of 20 to 30 minutes.

Phase 2 (Months 4 to 8): Load Progression. Introduce progressive resistance training with machines or free weights targeting hip extensors, back extensors, and quadriceps. Add brisk walking or low-impact aerobics 5 days per week. Monitor for any new back or hip pain, which warrants imaging before continuing loaded exercise.

Phase 3 (Months 9 to 12): Consolidation. Continue Phase 2 loads but add functional movement patterns: stair climbing with load, single-leg exercises, mild impact (heel drops, marching in place). These activities prime the skeleton for the transition to sequential antiresorptive therapy, which typically follows the romosozumab course.

Nutrition and Lifestyle Factors That Compound Exercise Benefits

Exercise and romosozumab both require adequate raw materials to build bone. Calcium and vitamin D are non-negotiable. The National Institutes of Health Office of Dietary Supplements recommends 1,200 mg of calcium daily for women over 50, ideally from food first (NIH ODS Calcium Fact Sheet). Vitamin D intake of 800 to 1,000 IU daily maintains serum 25-hydroxyvitamin D above 30 ng/mL, the threshold associated with reduced fracture risk in multiple meta-analyses (Bischoff-Ferrari et al., NEJM 2012).

Protein intake also matters. Muscle mass and bone mass are closely linked. Adults with osteoporosis should aim for 1.0 to 1.2 grams of protein per kilogram of body weight per day, per current European Society for Clinical and Economic Aspects of Osteoporosis guidelines (Rizzoli et al., Osteoporos Int 2018).

Smoking doubles fracture risk independent of BMD. Excessive alcohol consumption (more than two drinks per day) suppresses osteoblast activity and increases fall risk. Both should be discontinued while on romosozumab and beyond.

Monitoring Progress and Knowing When to Stop or Modify

DXA scanning at the end of the 12-month romosozumab course gives you the clearest picture of how much bone you built. The American Association of Clinical Endocrinology recommends repeating DXA 1 to 2 years after initiating anabolic therapy (Camacho et al., Endocr Pract 2020).

Stop exercise immediately and seek medical evaluation if you develop any of the following:

• Acute chest pain, pressure, or shortness of breath (possible MACE, the boxed-warning event)
• Sudden severe back pain, even without trauma (may signal a new vertebral fracture)
• Hip or groin pain after exercise (warrants hip X-ray to rule out stress fracture or femoral neck fracture)
• Jaw pain or new dental problems, though osteonecrosis of the jaw is far less common with romosozumab than with long-term bisphosphonate use

Patient-reported outcome data from FRAME showed that health-related quality of life scores, measured by the EQ-5D instrument, were significantly better in the romosozumab group than in the placebo group at 12 months, suggesting that most patients feel well enough during treatment to participate in regular physical activity (Cosman et al., NEJM 2016).

Transitioning From Romosozumab to Sequential Therapy: What Changes for Exercise

Romosozumab is always followed by an antiresorptive agent, typically alendronate or denosumab, to lock in the bone gains. In ARCH, the sequence of romosozumab followed by alendronate reduced hip fracture risk by 38% and vertebral fracture risk by 48% compared with alendronate alone (Saag et al., NEJM 2017). Exercise recommendations do not change significantly at that transition. The same weight-bearing, resistance, and balance program that served you during the romosozumab course remains appropriate and beneficial during antiresorptive therapy.

The cardiovascular boxed warning is specific to romosozumab. Once you transition to alendronate or denosumab, that particular concern no longer applies to the drug, though cardiovascular fitness remains important for your overall health.